FGFR1 expression correlates inversely with the efficacy of single-agent FGFR-specific inhibitors in pancreatic cancer.

Qingxiang LinAndrea SerratoreJonathan PerriTista Roy ChaudhuriJun QuWen Wee MaEugene KandelRobert M Straubinger

Published in: British journal of pharmacology (2023)

Single-agent FGFRi's mediate selective, molecularly-targeted suppression of PDAC proliferation, and their effects are greatest in PDAC tumors expressing low- to-moderate FGFR1.

Keyphrases

poor prognosis
signaling pathway
cancer therapy
high intensity
drug delivery